3
|
Koller D, Mitjans M, Kouakou M, Friligkou E, Cabrera-Mendoza B, Deak JD, Llonga N, Pathak GA, Stiltner B, Løkhammer S, Levey DF, Zhou H, Hatoum AS, Kember RL, Kranzler HR, Stein MB, Corominas R, Demontis D, Artigas MS, Ramos-Quiroga JA, Gelernter J, Ribasés M, Cormand B, Polimanti R. Genetic contribution to the comorbidity between attention-deficit/hyperactivity disorder and substance use disorders. Psychiatry Res 2024; 333:115758. [PMID: 38335780 PMCID: PMC11157987 DOI: 10.1016/j.psychres.2024.115758] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/27/2023] [Revised: 01/17/2024] [Accepted: 01/23/2024] [Indexed: 02/12/2024]
Abstract
We characterized the genetic architecture of the attention-deficit hyperactivity disorder-substance use disorder (ADHD-SUD) relationship by investigating genetic correlation, causality, pleiotropy, and common polygenic risk. Summary statistics from genome-wide association studies (GWAS) were used to investigate ADHD (Neff = 51,568), cannabis use disorder (CanUD, Neff = 161,053), opioid use disorder (OUD, Neff = 57,120), problematic alcohol use (PAU, Neff = 502,272), and problematic tobacco use (PTU, Neff = 97,836). ADHD, CanUD, and OUD GWAS meta-analyses included cohorts with case definitions based on different diagnostic criteria. PAU GWAS combined information related to alcohol use disorder, alcohol dependence, and the items related to alcohol problematic consequences assessed by the alcohol use disorders identification test. PTU GWAS was generated a multi-trait analysis including information regarding Fagerström Test for Nicotine Dependence and cigarettes per day. Linkage disequilibrium score regression analyses indicated positive genetic correlation with CanUD, OUD, PAU, and PTU. Genomic structural equation modeling showed that these genetic correlations were related to two latent factors: one including ADHD, CanUD, and PTU and the other with OUD and PAU. The evidence of a causal effect of PAU and PTU on ADHD was stronger than the reverse in the two-sample Mendelian randomization analysis. Conversely, similar strength of evidence was found between ADHD and CanUD. CADM2 rs62250713 was a pleiotropic SNP between ADHD and all SUDs. We found seven, one, and twenty-eight pleiotropic variants between ADHD and CanUD, PAU, and PTU, respectively. Finally, OUD, CanUD, and PAU PRS were associated with increased odds of ADHD. Our findings demonstrated the contribution of multiple pleiotropic mechanisms to the comorbidity between ADHD and SUDs.
Collapse
Affiliation(s)
- Dora Koller
- Department of Psychiatry, Yale School of Medicine, New Haven, CA, USA; Veterans Affairs Connecticut Healthcare Center, West Haven, CA, USA; Department of Genetics, Microbiology, and Statistics, Faculty of Biology, University of Barcelona, Catalonia, Spain.
| | - Marina Mitjans
- Department of Genetics, Microbiology, and Statistics, Faculty of Biology, University of Barcelona, Catalonia, Spain; Biomedical Network Research Centre on Mental Health (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain; Institute of Biomedicine of the University of Barcelona (IBUB), Barcelona, Catalonia Spain; Sant Joan de Déu Research Institute (IR-SJD), Esplugues de Llobregat, Catalonia, Spain
| | - Manuela Kouakou
- Department of Psychiatry, Yale School of Medicine, New Haven, CA, USA
| | - Eleni Friligkou
- Department of Psychiatry, Yale School of Medicine, New Haven, CA, USA; Veterans Affairs Connecticut Healthcare Center, West Haven, CA, USA
| | - Brenda Cabrera-Mendoza
- Department of Psychiatry, Yale School of Medicine, New Haven, CA, USA; Veterans Affairs Connecticut Healthcare Center, West Haven, CA, USA
| | - Joseph D Deak
- Department of Psychiatry, Yale School of Medicine, New Haven, CA, USA; Veterans Affairs Connecticut Healthcare Center, West Haven, CA, USA
| | - Natalia Llonga
- Psychiatric Genetics Unit, Group of Psychiatry Mental Health and Addiction, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Gita A Pathak
- Department of Psychiatry, Yale School of Medicine, New Haven, CA, USA; Veterans Affairs Connecticut Healthcare Center, West Haven, CA, USA
| | - Brendan Stiltner
- Department of Psychiatry, Yale School of Medicine, New Haven, CA, USA; Veterans Affairs Connecticut Healthcare Center, West Haven, CA, USA
| | - Solveig Løkhammer
- Department of Psychiatry, Yale School of Medicine, New Haven, CA, USA; NORMENT, Department of Clinical Science, University of Bergen, Bergen, Norway; Dr. Einar Martens Research Group for Biological Psychiatry, Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway
| | - Daniel F Levey
- Department of Psychiatry, Yale School of Medicine, New Haven, CA, USA; Veterans Affairs Connecticut Healthcare Center, West Haven, CA, USA
| | - Hang Zhou
- Department of Psychiatry, Yale School of Medicine, New Haven, CA, USA; Veterans Affairs Connecticut Healthcare Center, West Haven, CA, USA
| | - Alexander S Hatoum
- Department of Psychological and Brain Sciences, Washington University in Saint Louis, St. Louis, MO, USA
| | - Rachel L Kember
- Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; Mental Illness Research, Education and Clinical Center, Veterans Integrated Service Network 4, Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA
| | - Henry R Kranzler
- Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; Mental Illness Research, Education and Clinical Center, Veterans Integrated Service Network 4, Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA
| | - Murray B Stein
- Department of Psychiatry, University of California, San Diego, La Jolla, USA; Herbert Wertheim School of Public Health, University of California, San Diego, La Jolla, USA; VA San Diego Healthcare System, San Diego, CA, La Jolla, USA
| | - Roser Corominas
- Department of Genetics, Microbiology, and Statistics, Faculty of Biology, University of Barcelona, Catalonia, Spain; Institute of Biomedicine of the University of Barcelona (IBUB), Barcelona, Catalonia Spain; Sant Joan de Déu Research Institute (IR-SJD), Esplugues de Llobregat, Catalonia, Spain; Biomedical Network Research Centre on Rare Disorders (CIBERER), Instituto de Salud Carlos III, Madrid, Spain
| | - Ditte Demontis
- Department of Biomedicine - Human Genetics, Aarhus University, Aarhus, Denmark; The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus, Denmark; Center for Genomics and Personalized Medicine, Aarhus, Denmark; The Novo Nordisk Foundation Center for Genomic Mechanisms of Disease, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
| | - María Soler Artigas
- Department of Genetics, Microbiology, and Statistics, Faculty of Biology, University of Barcelona, Catalonia, Spain; Biomedical Network Research Centre on Mental Health (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain; Psychiatric Genetics Unit, Group of Psychiatry Mental Health and Addiction, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Mental Health, Hospital Universitari Vall d'Hebron, Barcelona, Spain
| | - Josep Antoni Ramos-Quiroga
- Department of Genetics, Microbiology, and Statistics, Faculty of Biology, University of Barcelona, Catalonia, Spain; Biomedical Network Research Centre on Mental Health (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain; Psychiatric Genetics Unit, Group of Psychiatry Mental Health and Addiction, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Psychiatry and Forensic Medicine, Universitat Autonoma de Barcelona, Barcelona, Spain
| | - Joel Gelernter
- Department of Psychiatry, Yale School of Medicine, New Haven, CA, USA; Veterans Affairs Connecticut Healthcare Center, West Haven, CA, USA; Department of Genetics, Yale School of Medicine, New Haven, CT, USA; Department of Neuroscience, Yale School of Medicine, New Haven, CT, USA
| | - Marta Ribasés
- Department of Genetics, Microbiology, and Statistics, Faculty of Biology, University of Barcelona, Catalonia, Spain; Biomedical Network Research Centre on Mental Health (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain; Psychiatric Genetics Unit, Group of Psychiatry Mental Health and Addiction, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Mental Health, Hospital Universitari Vall d'Hebron, Barcelona, Spain
| | - Bru Cormand
- Department of Genetics, Microbiology, and Statistics, Faculty of Biology, University of Barcelona, Catalonia, Spain; Institute of Biomedicine of the University of Barcelona (IBUB), Barcelona, Catalonia Spain; Sant Joan de Déu Research Institute (IR-SJD), Esplugues de Llobregat, Catalonia, Spain; Biomedical Network Research Centre on Rare Disorders (CIBERER), Instituto de Salud Carlos III, Madrid, Spain
| | - Renato Polimanti
- Department of Psychiatry, Yale School of Medicine, New Haven, CA, USA; Veterans Affairs Connecticut Healthcare Center, West Haven, CA, USA; Wu Tsai Institute, Yale University, New Haven, CT, USA
| |
Collapse
|